Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): an analysis of paediatric survey data from 56 countries

Yingfen Hsia, Brian R Lee, Ann Versporten, Yonghong Yang, Julia Bielicki, Charlotte Jackson, Jason Newland, Herman Goossens, Nicola Magrini, Mike Sharland on behalf of the GARPEC and Global-PPS networks*

Summary

Background Improving the quality of hospital antibiotic use is a major goal of WHO’s global action plan to combat antimicrobial resistance. The WHO Essential Medicines List Access, Watch, and Reserve (AWaRe) classification could facilitate simple stewardship interventions that are widely applicable globally. We aimed to present data on patterns of paediatric AWaRe antibiotic use that could be used for local and national stewardship interventions.

Methods 1-day point prevalence survey antibiotic prescription data were combined from two independent global networks: the Global Antimicrobial Resistance, Prescribing, and Efficacy in Neonates and Children and the Global Point Prevalence Survey on Antimicrobial Consumption and Resistance networks. We included hospital inpatients aged younger than 19 years receiving at least one antibiotic on the day of the survey. The WHO AWaRe classification was used to describe overall antibiotic use as assessed by the variation between use of Access, Watch, and Reserve antibiotics, for neonates and children and for the commonest clinical indications.

Findings Of the 23 572 patients included from 56 countries, 18 305 were children (77.7%) and 5267 were neonates (22.3%). Access antibiotic use in children ranged from 7.8% (China) to 61.2% (Slovenia) of all antibiotic prescriptions. The use of Watch antibiotics in children was highest in Iran (77.3%) and lowest in Finland (23.0%). In neonates, Access antibiotic use was highest in Singapore (100.0%) and lowest in China (24.2%). Reserve antibiotic use was low in all countries. Major differences in clinical syndrome-specific patterns of AWaRe antibiotic use in lower respiratory tract infection and neonatal sepsis were observed between WHO regions and countries.

Interpretation There is substantial global variation in the proportion of AWaRe antibiotics used in hospitalised neonates and children. The AWaRe classification could potentially be used as a simple traffic light metric of appropriate antibiotic use. Future efforts should focus on developing and evaluating paediatric antibiotic stewardship programmes on the basis of the AWaRe index.

Funding GARPEC was funded by the PENTA Foundation. GARPEC-China data collection was funded by the Sanming Project of Medicine in Shenzhen (SZSM2015120330). bioMérieux provided unrestricted funding support for the Global-PPS.

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

Introduction Antimicrobial resistance is a rapidly emerging global public health crisis. In response, the World Health Organization has published a global action plan on antimicrobial resistance,1 one of the aims of which is to optimise the use of antimicrobials. Knowledge gaps about the global use of antibiotics need to be addressed to inform the implementation and monitoring of antimicrobial stewardship activities. In 2014, WHO recommended improved surveillance of antibiotic use as one of its key strategies.2 Children are high users of antibiotics, but very little progress has been made with developing paediatric antibiotic stewardship programmes. One of the difficulties with developing such programmes is that the defined daily dose method used in adult antibiotic surveillance is not suitable for use in neonates and children, who have widely variable bodyweights.3,4 In March, 2017, the WHO Essential Medicines List (EML) Working Group classified antibiotics in the EML for Children (EMLc) into three groups: Access, Watch, and Reserve.3 The Access group contains generally narrow-spectrum antibiotics recommended as first and second choice for most common clinical infection syndromes. The Watch group contains generally broader spectrum antibiotic classes corresponding to the highest priority agents on the list of critically important antimicrobial drugs for human medicine.5 The Reserve group consists of last-resort antibiotics for targeted use in multidrug-resistant infections. These groups are collectively known as the AWaRe classification,6 and traffic light colour codes have been suggested to indicate the different categories:
Articles

Research in context

Evidence before this study
Data on patterns of antibiotic use in the paediatric population are mainly from high-income countries, whereas data from low-income and middle-income countries are scarce. We searched MEDLINE and Embase with the terms “point prevalence survey”, “antibiotic”, “pediatric”, “children”, and “neonate”, with age restriction (0–18 years) and no language restrictions; results were restricted to those published before April 14, 2018. A total of 17 relevant articles were included, of which one study was done through the European Surveillance of Antimicrobial Consumption project, 12 studies through the Antimicrobial Resistance and Prescribing in European Children network, and two were Indian studies from the Global Antimicrobial Resistance, Prescribing and Efficacy in Neonates and Children network. One study was done in Italian children’s hospitals, collecting data from patients hospitalised for more than 48 h by reviewing medical charts. A multicentre point prevalence survey (PPS) was done to assess inappropriate antibiotic use in hospitalised children in Turkey. These studies reported antibiotic prescribing patterns by means of the Anatomical Therapeutic Chemical classification. In March, 2017, the WHO Essential Medicines List for Children (EMLc) was updated and released a new antibiotic classification: Access, Watch, and Reserve (known as the AWaRe classification). We could identify no previous antibiotic use studies that applied the AWaRe classification in the inpatient paediatric population.

Added value of this study
We combined PPS data from three different study groups that all used similar methods. We applied the AWaRe classification to assess total and condition-specific patterns of antibiotic use for neonates and children in the hospital setting. Our study has shown the substantial variations of overall AWaRe antibiotics use in this population. Previous antibiotic stewardship programmes have used the defined daily dose system as the main tool to monitor patterns of antibiotic use. However, defined daily dose is complex and requires specialist knowledge of pharmacological and therapeutic systems. Additionally, defined daily dose cannot be applied to measure antibiotic use in the paediatric population owing to the wide variation in weights in hospitalised children. This study suggests that the AWaRe classification might be a simpler metric, and it could potentially be used in hospital antibiotic stewardship activities to monitor or compare antibiotic use between and within hospitals. Furthermore, the AWaRe classification could be a simple easy to understand indicator for clinicians and policy makers to identify issues of inappropriate antibiotic use and develop more specific guidance for antibiotic stewardship activities.

Implications of all the available evidence
We have shown that it is feasible to combine global PPSs originating from different study partners and subsequently categorise both overall and condition-specific patterns of antibiotic use by the AWaRe classification. Limitations include specific issues with the PPS methodology and the survey being biased towards long-stay patients when doing repeated PPS. Additionally, antibiotics not listed on the EMLc are not classified into an AWaRe category. Further refinement of the categories is required to take into account global patterns of use and formally evaluate this new method in stewardship programmes.

Methods

Data sources
Data were obtained from the GARPEC and Global-PPS networks. Both of these datasets come from point prevalence surveys (PPSs) of antibiotic use in hospitalised neonates and children. The PPS method has been used extensively to measure antimicrobial use in hospitalised adults and children.8–10 In both networks, participating centres contributed data voluntarily and received no financial incentives. This study was considered a clinical audit. Each participating hospital received local ethics approval if required. All data were anonymised without patient identifiers.

Data collection procedures
In 2015, a 1-day pilot PPS was done over 2 months in 11 countries that were part of the GARPEC network.
(Americas: three countries, four hospitals; Africa: one country, one hospital; Eastern Mediterranean: one country, one hospital; Europe: two countries, two hospitals; Western Pacific: two countries, four hospitals; South-East Asia: two countries, three hospitals). Following the pilot PPS study, four full-scale 1-day GARPECP PPSs were done between February, 2016, and February, 2017: February–March, 2016, May–June, 2016, September–October, 2016, and December, 2016–February, 2017. In total, 116 hospitals from 24 countries participated in at least one wave of the PPSs between 2015 and 2017 (Europe: ten countries, 34 hospitals; Americas: three countries, 39 hospitals; Western Pacific: five countries, 25 hospitals; Africa: three countries, five hospitals; South-East Asia: two countries, 12 hospitals; Eastern Mediterranean: one country, one hospital). Patient demographics (age, gender, bodyweight), comorbidity, antimicrobial agents, dose, frequency, route of administration, empirical or targeted treatment, and reasons for treatment were collected. Information on gestational age and birthweight were collected for neonates. The information collected in the pilot study was similar to that of the main waves of PPSs. GARPECP-data were collected via REDCap (Research Electronic Data Capture, Vanderbilt University, Nashville, TN, USA), a web-based application through which participating centres entered data online. All data were anonymised and linked only to an identification number unique to each participating centre. Additionally, 31 hospitals in the Sharing Antimicrobial Reports for Pediatrics Stewardship (SHARPS) project—a national antimicrobial stewardship collaboration between children’s hospitals in the USA—agreed to do a PPS using the GARPECP method and contribute their PPS data to the GARPEC network between June, 2016, and July, 2017.

A pilot Global-PPS was done between October and November, 2014. By means of a standardised surveillance method, detailed data on hospitalised adults, neonates, and children receiving an antimicrobial on the day of the survey were collected between January and September, 2015, from 335 hospitals in 53 countries: Europe (24 countries; 214 hospitals); Africa (five countries; 12 hospitals), Asia (16 countries; 57 hospitals), the Americas (six countries; 43 hospitals), and Oceania (two countries; nine hospitals). A web-based application was used for data entry, validation, and reporting designed by the University of Antwerp. Further details have been published elsewhere.10

We combined the GARPECP-PPS, SHARPS-PPS, and Global-PPS paediatric data for analysis. We only present variables that were collected in all datasets, including patient demographics, antibiotic use (type, route of administration, frequency of use), type of treatment (empirical or targeted treatment), and diagnosis. Neonates were defined as aged 30 days or younger and children were aged between 30 days and younger than 19 years. Antibiotic drugs were coded on the basis of the WHO Anatomical Therapeutic Chemical (ATC) classification system.12 We included antibiotics classified as antimicrobials for systemic use (ATC code: J01). Prescriptions for antifungal (ATC code: J02), antiviral (ATC code: J05), and drugs for tuberculosis (ATC code: J04) treatment were evaluated separately. Table 1 shows the list of antimicrobials included in the analysis, using the WHO ATC classification system. The list of antimicrobials was updated by the GARPECP Methodology Group in 2016. We excluded from our analysis the following antimicrobials: (i) vaccines, (ii) biologicals, (iii) anti-infective agents for topical use (ATC code: J02A), (iv) antifungal agents for topical use (ATC code: J02B), (v) antifungal agents for systemic use (ATC code: J02C), (vi) antiviral agents for topical use (ATC code: J05A), (vii) antiviral agents for systemic use (ATC code: J05B), and (viii) antiprotozoal agents (ATC code: B01). Table 2 shows the definitions of drug utilisation and antimicrobial stewardship groups. Table 3 shows the number of hospitals, children, and neonates included in the analysis. Figure 1 shows the regional patterns of 90% AWaRe antibiotic prescribing to children by drug utilisation.
Articles

Figure 2: Regional patterns of AWaRe antibiotic prescribing to neonates by drug utilisation 90%AWaRe=Access Watch, and Reserve. inhib=inhibitor.

Statistical analysis

Descriptive analyses were done separately for neonates and children. We described patterns of antibiotic use by using drug utilisation 90%, defined as the number of antibiotics that accounted for 90% of the total of antibiotics prescribed.11 The proportion of antibiotic use in each AWaRe category was calculated as the total number of Access, Watch, or Reserve prescriptions during the survey divided by the total number of antibiotic prescriptions, stratified by country and WHO region.

We then applied the AWaRe classification to treatment of the two most common clinical diagnoses, lower respiratory tract infection in children and sepsis in neonates.6,8 Prescriptions with missing data on patient demographics (eg, age and gender) were excluded from the analyses. Countries with a total number of prescriptions below the 25th percentile were included in the analyses but excluded from the graph presentations. Data management and analyses were done by means of Stata SE software version 14.0.

Role of the funding source

The sponsors of this study had no role in the study design, data collection, data analysis, data interpretation, or drafting of the manuscript. The corresponding author has full access to the final GARPEC dataset and access to a subset of completely anonymised Global-PPS data at institutional, ward, and patient level. The corresponding author has full responsibility for the decision to submit for publication.

Results

A total of 23,572 patients were included from 56 countries, of whom 18,305 (77·3%) were children and 5,267 (22·3%) neonates. A full list of included countries and hospitals is given in the appendix. The majority of participating

<table>
<thead>
<tr>
<th>Region</th>
<th>Countries</th>
<th>Hospitals</th>
<th>Total Prescriptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa</td>
<td>4</td>
<td>10</td>
<td>479 prescriptions</td>
</tr>
<tr>
<td>Americas</td>
<td>7</td>
<td>66</td>
<td>1,884 prescriptions</td>
</tr>
<tr>
<td>Eastern Mediterranean</td>
<td>6</td>
<td>11</td>
<td>194 prescriptions</td>
</tr>
<tr>
<td>Europe</td>
<td>28</td>
<td>116</td>
<td>1,890 prescriptions</td>
</tr>
<tr>
<td>South-East Asia</td>
<td>2</td>
<td>12</td>
<td>509 prescriptions</td>
</tr>
<tr>
<td>Western Pacific</td>
<td>6</td>
<td>28</td>
<td>1,298 prescriptions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Africa</th>
<th>Americas</th>
<th>Eastern Mediterranean</th>
<th>Europe</th>
<th>South-East Asia</th>
<th>Western Pacific</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gentamicin</td>
<td>138 (28%)</td>
<td>1884 (28·8%)</td>
<td>509 (28·9%)</td>
<td>371 (19·8%)</td>
<td>128 (6·8%)</td>
<td>119 (11·3%)</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>79 (16%)</td>
<td>706 (12·2%)</td>
<td>415 (22·0%)</td>
<td>317 (16·8%)</td>
<td>80 (5·7%)</td>
<td>74 (7·0%)</td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>12 (2·%  )</td>
<td>25 (0·5%)</td>
<td>103 (5·5%)</td>
<td>128 (6·8%)</td>
<td>77 (5·4%)</td>
<td>33 (3·0%)</td>
</tr>
<tr>
<td>Penicillins</td>
<td>15 (3·%  )</td>
<td>15 (0·3%)</td>
<td>55 (2·9%)</td>
<td>15 (0·8%)</td>
<td>40 (3·0%)</td>
<td>90 (8·5%)</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>9 (1·9%)</td>
<td>9 (0·2%)</td>
<td>52 (2·8%)</td>
<td>28 (1·5%)</td>
<td>68 (5·0%)</td>
<td>43 (4·1%)</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>5 (1·0%)</td>
<td>5 (0·1%)</td>
<td>30 (1·6%)</td>
<td>15 (0·8%)</td>
<td>39 (3·0%)</td>
<td>39 (3·5%)</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>8 (1·7%)</td>
<td>8 (0·1%)</td>
<td>10 (0·5%)</td>
<td>72 (3·9%)</td>
<td>10 (0·8%)</td>
<td>32 (2·8%)</td>
</tr>
</tbody>
</table>

See Online appendix

Table: Most frequently reported clinical indications for antibiotic prescribing in children and neonates

<table>
<thead>
<tr>
<th>Indication</th>
<th>Children (+1 month)</th>
<th>Neonates (+30 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial lower respiratory tract infection</td>
<td>23 (3%)</td>
<td>12 (5%)</td>
</tr>
<tr>
<td>Prophylaxis for medical problems</td>
<td>17 (0%)</td>
<td>8 (1%)</td>
</tr>
<tr>
<td>Prophylaxis for surgical disease</td>
<td>9 (4%)</td>
<td>6 (5%)</td>
</tr>
<tr>
<td>Sepsis</td>
<td>7 (0%)</td>
<td>2 (1%)</td>
</tr>
<tr>
<td>Febrile neutropenia or fever</td>
<td>6 (0%)</td>
<td>28 (3%)</td>
</tr>
<tr>
<td>Gastrointestinal tract infections</td>
<td>4 (5%)</td>
<td>2 (1%)</td>
</tr>
<tr>
<td>Skin or soft tissue infections*</td>
<td>4 (7%)</td>
<td>2 (1%)</td>
</tr>
<tr>
<td>Urinary tract infections</td>
<td>3 (8%)</td>
<td>1 (0%)</td>
</tr>
<tr>
<td>Upper respiratory tract infections</td>
<td>3 (3%)</td>
<td>1 (0%)</td>
</tr>
<tr>
<td>Newborn prophylaxis for newborn risk factors</td>
<td></td>
<td>12 (8%)</td>
</tr>
<tr>
<td>CNS infections</td>
<td>1 (0%)</td>
<td>4 (3%)</td>
</tr>
<tr>
<td>Newborn prophylaxis for maternal risk factors</td>
<td></td>
<td>4 (2%)</td>
</tr>
</tbody>
</table>
centres were from HICs (29 of 56), with 19 from upper-middle-income countries and eight from lower-middle-income countries. Figure 1 shows the variation between WHO regions in antibiotic prescribing to children. Ceftriaxone was the most commonly prescribed antibiotic to hospitalised children in Africa, the Eastern Mediterranean, Europe, and South-East Asia. Sulfamethoxazole–trimethoprim was the most commonly prescribed to children in the Americas and azithromycin in the Western Pacific region (figure 1). Gentamicin and ampicillin were commonly prescribed to hospitalised neonates in most regions (Africa, the Americas, the Eastern Mediterranean, Europe, and South-East Asia; figure 2). In the Western Pacific region, the use of amoxicillin and β-lactamase inhibitor, cefixime, and meropenem were high among hospitalised neonates (figure 2). Overall, lower respiratory tract infection, prophylaxis for medical problems, and prophylaxis for surgical disease were the most common diagnoses for children receiving antibiotics (table). Sepsis, newborn prophylaxis for newborn risk factors, and lower respiratory tract infection were the most common diagnoses for neonates.
Figure 3 shows the overall percentage of AWaRe antibiotics in hospitalised children by country. Slovenia had the highest percentage of Access antibiotic use (61·2%), followed by Spain (59·8%) and Chile (59·0%). China had the lowest percentage of Access antibiotic use (7·8%) among the included countries. The percentage of Watch antibiotic use in children was high in Iran (77·3%), China (74·1%), Montenegro (71·4%), and Macedonia (70·4%). The specific Watch drugs used differed between these countries (eg, the most commonly prescribed Watch antibiotics were ceftriaxone in Iran and azithromycin in China). Reserve antibiotics comprised a minority of prescriptions in all countries, being highest in children in Mexico (20·7%). The Reserve antibiotics included mainly the fourth generation cephalosporin cefepime to treat lower respiratory tract infection, febrile neutropenia, fever, or sepsis. Several countries reported a high proportion of unclassified antibiotics use in children; this was highest in Finland (60·3%), Georgia (38·3%), Latvia (25·0%), and Armenia (22·1%). The most commonly used unclassified antibiotics were cefuroxime, oxacillin, flucloxacillin, tobramycin, and trimethoprim.

In neonates, Singapore had the highest prevalence of Access antibiotic use (100·0%) and China the lowest (24·2%; figure 4). Watch antibiotic prescribing to neonates was highest in China (64·5%) and no Watch antibiotics were reported in Guinea. Compared with Access and Watch antibiotics, Reserve antibiotic prescribing was low in hospitalised neonates. Russia (13·9%) and Mexico (12·8%) reported the highest use of Reserve antibiotics, mainly cefepime and daptomycin. Several countries had a high proportion of unclassified antibiotic use, including Finland (52·6%), Germany (40·2%), Pakistan (35·0%), Italy (25·7%), and Canada (21·1%).
The percentage of children prescribed Access antibiotics for lower respiratory tract infection varied from 10·3% in the Western Pacific region to 69·7% in Africa (figure 5A). The percentage of children with lower respiratory tract infection prescribed Watch antibiotics varied from 22·9% in Africa to 73·2% in the Western Pacific. Variation in AWaRe antibiotic use was also observed between countries within the regions (figure 5B). In China, the use of Access antibiotics for lower respiratory tract infection treatment was very low (8·2%) compared with Australia (25·5%) and Japan (50·0%) in the Western Pacific region. In Africa, all children with lower respiratory tract infection received Access antibiotics for treatment in The Gambia. In Europe, Russia (5·7%) and Montenegro (5·6%) had the lowest percentage of Access antibiotic use; the highest percentage of Access antibiotic use was reported in the Netherlands (66·7%). Saudi Arabia had the lowest percentage of Access antibiotic use (17·7%) in the Eastern Mediterranean region. The high use of Watch antibiotics for childhood lower respiratory tract infection treatment in the Western Pacific region was owing to the high proportion of their use in China (76·1%). In the Americas, Canada reported a high percentage of Watch antibiotic use (61·5%) whereas Mexico had a high use of Reserve antibiotics (33·6%). Several European countries reported a high proportion of unclassified antibiotics use for lower respiratory tract infection treatment in children: Georgia (42·0%), Germany (33·3%), Latvia (27·5%), and Finland (25·0%).

Europe had the highest use of Access antibiotics (57·1%) for neonatal sepsis treatment and the Americas had the lowest use (28·6%; figure 6A). The proportion of Watch antibiotic use ranged from 35·1% (Europe) to 80·0% (Western Pacific) for neonatal sepsis.
to 56·1% (Mediterranean). The overall use of Reserve antibiotics was low, but was highest in the Americas (7·7%). The proportion of unclassified antibiotic use for neonates with sepsis was reported to be high in the Americas (14·2%) and low in the South-East Asia region (0·4%).

In the Americas, Chile reported the highest percentage of Access antibiotics (72·2%) and Mexico the lowest (50·0%; figure 6B). In the same region, Argentina reported high use of Watch antibiotics (42·9%) and Brazil the lowest use (16·4%). Mexico reported the highest use of Reserve antibiotics for neonatal sepsis treatment (16·7%), followed by the USA (2·9%) and Brazil (1·0%). In Africa, the use of Access antibiotics was low in South Africa (33·3%) and high in Nigeria (52·9%). In Ghana, the use of unclassified antibiotics was considerable (38·5%) compared with Nigeria (4·0%) and South Africa (0·0%). In Europe, Finland had the lowest percentage of Access antibiotic use for neonatal sepsis treatment (25·0%), mainly owing to the high use of unclassified antibiotics (62·5%). Only two European countries reported Reserve antibiotic use: Serbia (23·5%) and Greece (2·5%). In the South-East Asia region, Thailand reported high use of Access antibiotics for neonatal sepsis treatment (74·2%), whereas the use was lower in India (30·7%). In the Western Pacific region, China had the lowest use of Access antibiotics (27·1%) and Australia the highest (75·2%).

Discussion
To our knowledge this is the first global collaborative study of patterns of antibiotic use in hospitalised children that used the WHO AWaRe classification. We have observed substantial variation between countries in the use of Access, Watch, and Reserve antibiotics in neonates and children. In children, Access antibiotic use ranged from 7·8% in China to 61·2% in The Gambia; and Watch antibiotic use ranged from 23·0% in Finland to 77·3% in Iran. There was also substantial variation in patterns of antibiotic use for treatment of neonatal sepsis and paediatric lower respiratory tract infection.

No recognised standards exist for antibiotic prescribing at a population level that would enable us to define the appropriateness of antibiotic use for neonates and children. Therefore, comparisons between countries should be interpreted cautiously. Total amounts of antibiotic prescribing are recognised to vary substantially between and within countries even across Europe.\(^\text{44}\) Important influences are disease burden, including the prevalence of infections caused by highly resistant bacteria; local health-care service issues (eg, infrastructure, staffing); and pricing and affordability of antibiotics. For example, the availability of some narrow-spectrum antibiotics, such as phenoxymethylpenicillin, is very low in many HIC and LMIC countries.\(^\text{45}\) Patterns of antimicrobial resistance (particularly for conditions such as sepsis or urinary tract infections) are likely to be key drivers, but also difficult to identify when defining amounts of appropriate use of Access antibiotics. However, for some conditions, such as childhood lower respiratory tract infection, WHO guidance clearly recommends Access antibiotics (eg, amoxicillin) even in countries with high prevalence of pneumococcal resistance. Consequently, although opportunities exist to incorporate this AWaRe classification within paediatric antibiotic stewardship programmes, the situation is clearly more complex than simply increasing prescriptions for Access antibiotics. It might however be possible in the future to combine metrics from several data sources to improve estimates of appropriateness of antibiotic prescribing in this population.\(^\text{46}\) A further challenge is that several commonly prescribed narrow-spectrum antibiotics (eg, second-generation cephalosporins, trimethoprim) are not included in the AWaRe classification as these antibiotics are not listed on the EMLc, resulting in a high proportion of unclassified antibiotic use for certain countries. The EML Working Group acknowledges the limitations of this new antibiotic classification and suggests further revision over time.\(^\text{17}\)

Other studies have evaluated antibiotic use in children at the national or regional level.\(^\text{43,46–49}\) Consistent with previous studies, lower respiratory tract infection and sepsis were the most common diagnoses in our study for children and neonates receiving antibiotics for treatment.\(^\text{8,9}\) We found that the range of antibiotics used is much smaller in neonates than in children, which is also in line with previous studies.\(^\text{43}\) This might be owing to the high use of the two key Access antibiotics, ampicillin and gentamicin, in line with the WHO recommendation for sepsis treatment in neonates. The most commonly prescribed antibiotic in children was ceftriaxone (third-generation cephalosporin), again in agreement with previous studies.\(^\text{43}\) We observed a high proportion of Watch antibiotic use in Iranian children in our analysis. A multicentre PPS study in Iran has reported high use of third-generation antibiotics (ceftriaxone, cefotaxime, and cefazedime) and vancomycin in children.\(^\text{24}\) The consistency of our results with previous studies suggests that patterns of use have changed little over time, with little evidence of improvement in the quality of prescribing.

Several metrics have been developed in support of paediatric antibiotic stewardship programme interventions such as defined daily doses, day of treatment, length of treatment, and prescribed daily dose, but all of these are quite complex to measure and not easy to communicate back to prescribers. The AWaRe classification aims to provide an easily interpretable framework for broad assessment of patterns of narrow-spectrum and broad-spectrum antibiotic use. The patterns of use can be derived on the basis of the EMLc guidance for particular Access antibiotics for specific clinical conditions.\(^\text{29}\)

The strength of this study lies in the collaboration between different research groups combining data, thus allowing a wide coverage of countries and regions.
The use of a simple, relatively cheap, cross-sectional PPS method allowed the collection of data in LMICs, where surveillance and stewardship programmes are not routinely available. However, although the PPS design has been extensively used to evaluate antibiotic use, it has some limitations.\(^{32,33}\) It cannot capture treatment duration, switching patterns, or clinical outcomes, and is more likely to collect antibiotic data from long-stay hospital patients and longer treatment courses. The repeated PPS at different time points might introduce bias in the case mix.\(^{32}\) Furthermore, participating centres contributed data to the GARPEC and Global-PPS networks voluntarily, so our study might not be generalisable to the overall inpatient paediatric population. The data collection and data entry require clinicians and hospital staff to spend time going through medical notes and is clearly biased towards larger tertiary academic institutions in HICs (only one centre in a low-income country was included). Equally importantly, many participating centres did not collect data in all their neonatal or paediatric wards in their hospitals so the results might not be representative within hospitals. Additionally, we have not as yet investigated the variation of antibiotic use between hospitals in one country, and would not be able on the basis of available data to establish whether higher level factors, such as hospital infrastructure and resources, affect antibiotic use. Thus, more detailed country-specific analyses are required to further explore factors that affect antibiotic use between tertiary and district hospitals. There is also the possibility of an observer effect when doing repeated PPSs (GARPEC), whereby participation in the study causes changes in prescribing behaviour. However, our results were similar to previous studies of antibiotic use,\(^{32,33}\) suggesting that any such biases were minimal. Finally, there might also be seasonal variations in antibiotic use that we have not assessed.\(^{32,33}\)

The methods for antibiotic PPSs are now well established, whereby countries develop their own online tools at national level. However, it has proved easier to measure and monitor patterns of antibiotic use than to change them. Further work needs to focus on appropriate overall amounts of antibiotic use in both the community and hospital settings. However, condition-specific AWARe metrics can show, for example, the marked variation in the overall proportion of children receiving Access antibiotics for lower respiratory tract infection, which cannot readily be explained on the basis of WHO guidelines. Risk adjustment models therefore need to be developed for different clinical conditions, focusing on both prevalence of underlying disease (HIV, malnutrition) and resistance profiles.\(^{32,33}\) Furthermore, establishing whether the same variation in prescribing patterns according to AWARe categories is also seen in the adult population is important. This study has shown that use of a simple PPS method is feasible to assess patterns of AWARe antibiotic use in hospitalised children globally. National and international ambitions for the proportion of children in hospital treated with Access antibiotics could potentially be assessed by means of the AWARe PPS method.

**Contributors**

YH, JB, and MS conceived the idea and contributed to the design of data collection tools for the GARPEC project. YY contributed to the data collection and management for Chinese hospitals. BRL and JN contributed to the design, conduct, data management and analyses of the SHARP project. AV and HG contributed to the study design and conduct of the Global-PPS project. YH, Cj, JB, and AV contributed to the final dataset manipulation for the GARPEC, SHARP5, and Global-PPS projects. YH and Cj contributed to data management, analyses, and interpretation and writing of the manuscript. All authors were involved with drafting and essential revisions of the manuscript.

**Members of the GARPEC network**

I. Teston (Eurekian General Hospital, Buenos Aires, Argentina), K Cheung (Monash Children’s Hospital, Melbourne, VIC, Australia), S Koning (Box Hill Hospital—Eastern Health, Melbourne, VIC, Australia), R Grimwood, J Cross (Gold Coast University Hospital, Southport, QLD, Australia), A da Silva (Prontobaby Children’s Hospital and Hospital Domingos Lourenco, Rio de Janeiro, Brazil), D Beradou (Roberto del Rio Children’s Hospital, Santiago, Chile), WS Zhang (Tianjin Children’s Hospital, Tianjin, China), W Zhao (Shandong University, Shandong, China), G Liu, KL Shen, KH Yao (Beijing Children’s Hospital Affiliated to Capital Medical University, Beijing, China), YJ Zheng, JG Deng, JS Zhang, (Shenzhen Children’s Hospital, Shenzhen, China), Y Wang, XY Jiang (Fudan University Pediatric Hospital, Shanghai, China), DY Tian, CM Jing (Chongqing Children’s Hospital, Chongqing, China), UJ Wang, SC Cao (Xi’an Children’s Hospital, Xian, China), UJ Wu, X Chen (Shenzhen Baoan Women and Children’s Hospital, Shenzhen, China), MJ Ding, L Zhang (Jinan Children’s Hospital, Jinan, China), U Liu, YH Yang (Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China), G Cao, W Wang (The Shanghai Children’s Medical Centre of Shanghai Jiaotong University, Shanghai, China), JP Li, LF Tang (The Children’s Hospital and Zhejiang University School of Medicine, Hangzhou, China), L Liu, P Wang (Beijing Obstetrics and Gynaecology Hospital, Capital Medical University, Beijing, China), J Qian, CM Zhu (Capital Institute of Paediatrics, Beijing, China), G Lu, QL Deng (Guangzhou Women and Children’s Medical Centre, Zhihuang, China), XP Mu, CA Zhao (Guangdong Provincial Women and Children’s Health Care Hospital, Shenzhen, China), XY Dong, H Zhang (Shanghai Children’s Hospital, Shanghai, China), CY Li, W Li (The First Hospital of Jinlin University, Changchun, China), H Sazen, S Kekomaki (Children’s Hospital, University of Helsinki, Helsinki, Finland), M Hufnagel, B Rippberger (University Medical Centre, Medical Faculty, University of Freiburg, Freiburg, Germany), M Knuf, P Nikolic (Children’s Hospital Wiesbaden, Wiesbaden, Germany), J Hübner, K Kreitmeyer (Ludwig-Maximilians-University, Munich, Germany), U Behrends, N Rieber (Technical University Hospital Munich, Munich, Germany), H Renk (University Children’s Hospital Tübingen, Tübingen, Germany), M Spyridis, M Tsolia (P. and A. Kyriakou Children’s Hospital, Athens, Greece), V Papaevangelous (University General Hospital Attikon, Athens, Greece), D Gkentzi (University Hospital of Patras, Patras, Greece), G Syriopanopoulos, K Kaffe (University of Thessaly, Larissa, Greece), E Rodieres, G Pinava, E Papadimitriou, E Josifidis (Hippokration Hospital, Thessaloniki, Greece), S Gandar, R Laxminarayan (Centre for Disease Dynamics, Economics and Policy, New Delhi, India), G Alvarez-Urria, D Jinke (Rural Development Trust Hospital—Bathalapalli, Andhra Pradesh, India), Srinivas Murki, H Kandrujai (Fernandez Hospital, Hyderabad, India), S Singh, A K Vasudev (Amrita Institute of Medical Sciences, Kochi, India), R Kanhini, A Akula (Sowmya Children’s Hospital, Hyderabad, India), A Chikappa, O Tung (Rural Development Trust Hospital—Kalyanadurgam, India), S Subramanian (Paramitha Children’s Hospital, Hyderabad, India), A Sharma (Portis Hospital, Mohali, India), D Dharapalan (Dr Tewale Multispeciality Hospital for Children, Navi Numbh, India), I Ashkenazi-Hoffnung, S Ashkenazi (Schneider Children’s Medical Centre, Petah Tikva, Israel), E Esposito (University of Perugia, Perugia, Italy), C Tagliabue (Fondazione IRCCS Ca’Granda, Ospedale Maggiore

For more on the National Antimicrobial Prescribing Survey see https://www.naps.au/Default.aspx
Tirana, Albania), W Cornistein, Hospital Cosme Argerich and Instituto D Lacej (University Hospital Centre “Mother Theresa”, Tirana, Albania), Members of the Global-PPS network S Weissman, A Brothers (Seattle Children’s Hospital, WA, USA), TX, USA), A Hersh, J Olsen (Primary Children’s Hospital, UT, USA), M Chang, H Orr (University of Texas–Houston, (Cook Children’s Hospital, TX, USA), K Merkel, M Fernandez (Seton Healthcare, TX, USA), R Banerjee, J Gillon (Nationwide Children’s hospital, OH, USA), T Metjian, J Gerber, C Boge (Stony Brook Children’s Hospital, NY, USA), Joshua Courter and J Zweiner (Children’s Hospital of Omaha, NE, USA), Saul R Hymes (Children’s National Medical Center, DC, USA), L Handy, S Chan (Connecticut Children’s Hospital, CT, USA), R Hamdy, B Hammer (Children’s National Medical Center, DC, USA), I Handy, S Chan (Alfred DuPont, DE, USA), K Namith, D Berman (All Children’s Hospital, FL, USA), A J Fernandez, C Shapiro (Children’s Healthcare of Atlanta, GA, USA), M Heger, G Johnson (Children’s Hospital of Illinois, IL, USA), S J Patel (Lurie Children’s, Illinois, USA), J Nichols, J Manaloee (Riley Hospital for Children, Indiana, USA), K Flett, S Jones (Boston Children’s, Massachusetts, USA), R Olivero, S Ogrin (Helen DeVos Children’s hospital, MA, USA), J Goldwyn, K Patel (Children’s Mercy-Kansas City, MO, USA), M Nelson, J Newland (St Louis Children’s hospital, MO, USA), A Green, J Zweiner (Children’s Hospital of Omaha, NE, USA), Saul R Hynes (Stony Brook Children’s Hospital, NY, USA), Joshua Courter and David Haslam (Cincinnati Children’s, OH, USA), P Jaggi, J Tansmore ( Nationwide Children’s hospital, OH, USA), T Metjian, J Gerber, C Boge (The Children’s Hospital of Philadelphia, PA, USA), K Lee, S Arnold Le Bonheur Children’s hospital, TN, USA), R Banerjee, J Gillon (Vanderbilt University Medical Center, TN, USA), I Castagnini, S Kubies (Children’s Hospital of San Antonio, TX, USA), M Mazade, M Crawford (Cook Children’s Hospital, TX, USA), K Merkel, M Fernandez (Seton Healthcare, TX, USA), M Chang, H Orr (University of Texas–Houston, TX, USA), A Hersh, J Olsen (Primary Children’s Hospital, UT, USA), S Weissman, A Brothers (Seattle Children’s Hospital, WA, USA), S Henderson (American Family Children’s – Madison, WI, USA).

Members of the Global-PPS network D Lacey (University Hospital Centre “Mother Theresa”, Tirana, Albania), I Hodha (Department of Pharmacy, University of Medicine Tirana, Tirana, Albania), W Cornstein, Hospital Cosme Argerich and Instituto FLENI, Buenos Aires, Argentina), R Quirós (Hospital Universitario Austral, Buenos Aires, Argentina), M Hojman (Hospital “Bernardino Rivadavia”—Municipal Government, Buenos Aires, Argentina), M Del Castillo (FLENI, Buenos Aires, Argentina), I Ghazaryan (Scientific Centre of Drug and Medical Technology Expertise of MoH, Yerevan, Armenia), J AL-Salman (Salamiya Medical Complex, Manama, Bahrain), D Konopnicki (Saint-Pierre University Hospital, Brussels, Belgium), D Pierard (Universitair Ziekenhuis Brussel, Brussels, Belgium), X Holmenn (Grand Hôpital de Chatelleron, Chartres, France), P Schelstraete (Ghent University Hospital, Ghent, Belgium), E Firre (CHR de Liège, Liège, Belgium), B Van Herendael (GZA Hospitals, Wilrijk, Belgium), A Dedene-Ljubovic (Clinical Centre University Sarajevo Sarajevo, Bosnia and Herzegovina), A Pignatari (Universidade Federal de São Paulo, São Paulo, Brazil), D Sahabu (Alberta Health Services, Calgary, Canada), C Carvajal, R Alvaro (Department of Infectious Disease, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile), J Labarca (Department of Infectious Diseases, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile), A Solano (Hospital Calderon Guarda, San Jose, Costa Rica), C Ramirez (Hospital México, San José, Costa Rica), I Mareková, J Horváth (University Hospital Centre Zagreb, Zagreb, Croatia), I Pristas (University Hospital for Infectious Diseases, Zagreb, Croatia), E Marshall (University Hospitals Bristol NHS Foundation Trust, Bristol, UK), K Kuk, K Kuk (Hospital for Children, University of Illinois, Chicago), (Department of Child and Adolescent Medicine, Tbilisi State Medical University, Tbilisi, Georgia), A Neuert (Department of Paediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany), M Hufnagel, Division of Pediatric Infectious Diseases and Rheumatology, Department of Paediatrics and Adolescent Medicine, University Medical Centre, Medical Faculty, University of Freiburg, Freiburg, Germany), A Eninilli (Komfo Anokye Teaching Hospital, Kumasi, Ghana), J A Fripondg (Komfo Anokye Teaching Hospital, Kumasi, Ghana), E Rolides, E Tasis (Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece), J Soltani (Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran), D Fitzgerald (National Maternity Hospital, Dublin, Ireland), S Esposito (University of Perugia, Perugia, Italy), K Kassahara (Nara Medical University, Kashihara, Japan), Y Gu (Toho University Hospital, Sendai, Japan), Y Horikoshi (Tokyo Metropolitan Children’s Medical Centre, Tokyo, Japan), K Okinaka (National Cancer Centre Hospital, Tokyo, Japan), H Kunishima (Tama Municipal Hospital, Kawasaki, Japan), F Darwish Elhajji (Faculty of Pharmacy, Applied Science Private University, Amman, Jordan), M Alshehr (King Fahad Medical City, Children’s Hospital of Riyadh, Saudi Arabia), I Raka (National Institute for Public Health of Kosovo and University of Pristhina “Hasan Prishtina”, Pristhina, Kosovo, in accordance with UN Security Council resolution 1244 (1999)); B Kambaraleva, Tømnok Municipal Hospital, Tømnok, Kyrgyzstan, I Sviestina (University Children’s Hospital and University of Latvia, Riga, Latvia), S Burokience (Vilnius University Institute of Clinical Medicine, Clinic of Childhood Diseases, Vilnius, Lithuania), V Usonis (Vilnius University Institute of Clinical Medicine, Clinic of Childhood Diseases, Vilnius, Lithuania), E Shaqiri (Institute of Public Health, Skopje, Northern Macedonia), P Zari (Mater Dei Hospital, Msida, Malta), G Markovic (Institute for Children’s Diseases, Podgorica, Montenegro), S Simovic (Health Insurance Fund, Podgorica, Montenegro), P Nwaihji-Pricewil (National Hospital Abuja, Nigeria), K Iregbu (National Hospital Abuja, Nigeria), A Aboderin (Obafemi Awolowo University Teaching Hospital, Ilesa, Nigeria), O Oduyobo (Lagos University teaching hospital, Lagos, Nigeria) A Olayinka (Ahmadu Bello University Teaching Hospital, Zaria, Nigeria), A McCorr (Southern Health and Social Care Trust, Craigavon, Northern Ireland), B McCullagh (South Eastern Health and Social Care Trust, Dundonald, Northern Ireland), C Gormley (Western Health and Social Care Trust, Derry, Northern Ireland), S Rachina (Russian Friendship University, Moscow, Russia), B Karacic (Clinical Centre of Serbia, Belgrade, Serbia), SM Chun, HH Chen (National University Hospital, Singapore), ML Ling (Singapore General Hospital, Singapore), H Finlayson, (Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa), P Terol Barrero (Virgen Macarena University Hospital, Seville, Spain), P Buitjels (Meander Medical Centre, Amersfoort, Netherlands),.
GARPEC is funded by the PENTA Foundation. GARPEC institutions with which they are affiliated. We are grateful to all alone are responsible for the views expressed in this Article and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. We are grateful to all members of the GARPEC, SHARP, and Global-PPS networks for their participation in data collection.

References